Review
Oncology
Mahendra Naidoo, Peter Gibbs, Jeanne Tie
Summary: Circulating tumour DNA (ctDNA) shows promise in detecting microscopic residual disease in patients post bowel cancer surgery, potentially personalizing treatment and increasing cure rates.
Article
Oncology
Li Yang, Jinlin Yang, Andreas Kleppe, Havard E. Danielsen, David J. Kerr
Summary: The current standard-of-care adjuvant treatment for patients with colorectal cancer is chemotherapy selected on the basis of conventional histopathological staging criteria; however, the clinical benefit from these regimens is limited. The authors of this Perspective discuss strategies to minimize toxicity and monitor efficacy of these regimens, and propose new tools for disease staging that could enable more personalized treatment decisions.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Psychology, Multidisciplinary
Maria Romero-Elias, David Gonzalez-Cutre, Vicente J. Beltran-Carrillo, Alejandro Jimenez-Loaisa
Summary: This study explored the experiences of basic psychological needs, motivation to continue living, and psychological well-being in colorectal cancer patients during adjuvant treatment. Hope was found to be a relevant source of motivation and had a positive impact on the patients' psychological well-being.
CURRENT PSYCHOLOGY
(2023)
Article
Oncology
Yuchong Yang, Yao Lu, Hui Tan, Ming Bai, Xia Wang, Shaohua Ge, Tao Ning, Le Zhang, Jingjing Duan, Yansha Sun, Rui Liu, Hongli Li, Yi Ba, Ting Deng
Summary: The timing of postoperative adjuvant chemotherapy has significant effects on the survival rate of colorectal cancer patients. Starting chemotherapy within 8 weeks after surgery leads to better outcomes. There is no noticeable difference in survival benefits between starting chemotherapy within 5-8 weeks and within <= 4 weeks. Delaying chemotherapy for approximately 5-6 months after surgery is still beneficial in improving prognosis compared to patients not receiving chemotherapy.
Article
Oncology
Yuanyuan Chen, Mingyue Xu, Qianwen Ye, Jia Xiang, Tianhui Xue, Tao Yang, Long Liu, Bing Yan
Summary: Irregular delay of adjuvant chemotherapy (IDacT) has a significant impact on the prognosis of stage II-III colorectal cancer (CRC) patients, and the effect of delay per cycle (DpC) is more pronounced, resulting in significantly worse disease-free survival (DFS) for patients with longer DpC.
Review
Biochemistry & Molecular Biology
Anusha Chidharla, Eliot Rapoport, Kriti Agarwal, Samragnyi Madala, Brenda Linares, Weijing Sun, Sakti Chakrabarti, Anup Kasi
Summary: Emerging data suggests that ctDNA can serve as a reliable biomarker for MRD in CRC patients, with implications for recurrence risk assessment and patient selection for adjuvant chemotherapy. A meta-analysis of 23 studies including 3568 CRC patients demonstrated that post-operative ctDNA-positive patients had a significantly higher risk of recurrence compared to ctDNA-negative patients. Subgroup analysis showed varying HRs for different disease stages and the use of adjuvant chemotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Kazuaki Okamoto, Hiroaki Nozawa, Shigenobu Emoto, Koji Murono, Kazuhito Sasaki, Soichiro Ishihara
Summary: This study aimed to investigate the tolerability and efficacy of adjuvant CAPOX therapy in elderly patients compared to young patients. The results showed that adjuvant CAPOX therapy was well-tolerated in elderly Japanese patients, and the prognosis of elderly patients with stage III CRC was similar to that of their younger counterparts. Therefore, advanced age may not be a contraindication for adjuvant chemotherapy in CRC.
Article
Oncology
Yi Pan, Jia-Tao Zhang, Xuan Gao, Zhi-Yong Chen, Bingfa Yan, Pei-Xin Tan, Xiao-Rong Yang, Wei Gao, Yuhua Gong, Zihan Tian, Si-Yang Maggie Liu, Hui Lin, Hao Sun, Jie Huang, Si-Yang Liu, Hong-Hong Yan, Song Dong, Chong-Rui Xu, Hua-Jun Chen, Zhen Wang, Pansong Li, Yanfang Guan, Bin-Chao Wang, Jin-Ji Yang, Hai-Yan Tu, Xue-Ning Yang, Wen-Zhao Zhong, Xuefeng Xia, Xin Yi, Qing Zhou, Yi-Long Wu
Summary: This prospective study found that ctDNA concentrations significantly decreased during chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer. Patients with early undetectable ctDNA had better survival outcomes, suggesting a potential role for ctDNA as a predictive biomarker. Furthermore, pretreatment ctDNA variants were found to be essential for MRD detection.
Review
Oncology
Laura Masfarre, Joana Vidal, Concepcion Fernandez-Rodriguez, Clara Montagut
Summary: Detection of minimal residual disease (MRD) through circulating tumor DNA (ctDNA) has emerged as a powerful prognostic biomarker for identifying patients at higher risk of recurrence following surgery for localized colorectal cancer (CRC). Clinical trials are ongoing to evaluate the impact of ctDNA-guided treatment on improving clinical outcomes for CRC patients.
Article
Medicine, Research & Experimental
Cecilia Villegas, Rebeca Perez, Olov Sterner, Ivan Gonzalez-Chavarria, Cristian Paz
Summary: Colorectal cancer is the second leading cause of cancer death worldwide, mainly affecting men, with about 20% of cases due to hereditary syndromes. Curcumin, the main polyphenol pigment in turmeric, has antioxidant properties and synergistic effects with both anticancer and anti-inflammatory drugs in inhibiting the progression of CRC through multiple signaling pathways.
Article
Sport Sciences
Ingunn Hatlevoll, John-Arne Skolbekken, Line Merethe Oldervoll, Arne Wibe, Eva Hofsli
Summary: This study explores the experiences of colorectal cancer patients participating in supervised exercise program during adjuvant chemotherapy. Findings indicate that scheduled appointments and individual adjustments in exercise can improve adherence and inner motivation, leading to positive effects on patients both mentally and physically.
SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS
(2021)
Review
Oncology
Mahendra Naidoo, Oliver Piercey, Jeanne Tie
Summary: The use of ctDNA in colorectal cancer treatment shows potential in individualizing treatment, guiding targeted therapy selection, and providing a surrogate marker for treatment response. The results of randomized clinical trials will determine if ctDNA can be truly incorporated into clinical practice in the future.
CURRENT ONCOLOGY REPORTS
(2021)
Article
Oncology
Timothy J. Iveson, Alberto F. Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang-Shu Ou, Jeffrey P. Meyers, Qian Shi, Axel Grothey, Mark P. Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels H. Hollander, Fabio Galli, Kentaro Yamazaki, Vassilis Georgoulias, Rachel Kerr, Eiji Oki, Sara Lonardi, Andrea Harkin, Gerardo Rosati, James Paul
Summary: This study aimed to investigate the impact of reducing the duration of oxaliplatin adjuvant chemotherapy on patients with high-risk stage II colon cancer, and the results showed that noninferiority of 3-month treatment was not demonstrated.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Hayoung Lee, Seung-Yeon Yoo, In Ja Park, Seung-Mo Hong, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Summary: This retrospective analysis evaluated the prognostic implications of lymphovascular invasion (LVI) in patients with pT3N0 colorectal cancer and its relationship with adjuvant chemotherapy. It was found that LVI was associated with recurrence-free survival (RFS) but not with overall survival (OS). The underestimation of LVI diagnosis could lead to low recurrence rate predictions, and further consideration is needed when using LVI as a guiding factor for adjuvant chemotherapy.
Article
Pharmacology & Pharmacy
Sijie Zha, Ting Li, Qingshan Zheng, Lujin Li
Summary: This study clarifies the benefits and risks of postoperative adjuvant chemotherapy compared with surgery alone in patients with stage II/III colorectal cancer using model analysis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony Frank Shields, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Frank A. Sinicrope, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A. Meyerhardt, Thierry Andre, Demetris Papamichael, Julien Taieb
Summary: Whether early discontinuation of all treatment or early discontinuation of oxaliplatin could worsen the prognosis in patients with stage III CC remains unknown.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Surgery
Hirofumi Hasuda, Tetsuo Ikeda, Yutaka Makizaki, Haruka Yokota, Yoshiki Tanaka, Hiroshi Ohno, Mototsugu Shimokawa, Hiroya Matsuoka, Yasue Kimura, Eiji Oki, Tomoharu Yoshizumi
Summary: The gut microbiome of patients with esophageal squamous cell carcinoma is altered, with differences in microbial diversity and composition compared to healthy individuals. These alterations are more pronounced after surgical intervention.
Article
Oncology
Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, Masato Nakamura, Jun Watanabe, Hitoshi Ojima, Akitaka Makiyama, Masahito Kotaka, Hiroki Hara, Yoshinori Kagawa, Naotoshi Sugimoto, Hisato Kawakami, Atsuo Takashima, Takeshi Kajiwara, Eiji Oki, Yu Sunakawa, Soichiro Ishihara, Hiroya Taniguchi, Takako Eguchi Nakajima, Satoshi Morita, Kuniaki Shirao, Naruhito Takenaka, Daisuke Ozawa, Takayuki Yoshino
Summary: This study assessed the noninferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab as second-line treatment for metastatic colorectal cancer (mCRC) compared to fluoropyrimidine and irinotecan plus bevacizumab. The results showed that FTD/TPI plus bevacizumab did not demonstrate superiority over the control group in mCRC second-line treatment.
BRITISH JOURNAL OF CANCER
(2023)
Article
Engineering, Electrical & Electronic
Han Zhang, Fujun He, Eiji Oki
Summary: This paper proposes a shared backup allocation model for middleboxes considering the workload-dependent failure rate of backup servers. The simulated annealing algorithm is used to solve this problem. Experimental results show that the proposed model can reduce the maximum unavailability by an average of 29% compared to the baseline model under different conditions.
IEICE TRANSACTIONS ON COMMUNICATIONS
(2023)
Article
Oncology
Qingjiang Hu, Eiji Oki, Teppei Yamada, Tomomi Kashiwada, Hideto Sonoda, Masato Kataoka, Hirofumi Kawanaka, Yasushi Tsuji, Akitaka Makiyama, Yuichiro Nakashima, Mitsuhiko Ota, Yasue Kimura, Tomoharu Yoshizumi
Summary: By analyzing the genomic characteristics of HER2-positive and negative gastric cancer, we found that several gene alterations in the HER2 pathway may be the potential mechanism underlying trastuzumab resistance, and HER2-negative gastric tumors with ARID1A mutation may be sensitive to immune checkpoint inhibitors.
Article
Oncology
Kentaro Yamazaki, Satoshi Yuki, Eiji Oki, Fumikazu Sano, Misako Makishima, Kenichi Aoki, Tetsutaro Hamano, Kouji Yamamoto
Summary: In this study, the baseline characteristics and efficacies of intensive and less intensive therapies for metastatic colorectal cancer were compared. Patient age and daily activity levels were found to be important factors in determining treatment intensity.
Article
Oncology
Mitsuhiko Ota, Hiroshi Saeki, Hideo Uehara, Yoshiko Matsuda, Satoshi Tsutsumi, Tetsuya Kusumoto, Hisateru Yasui, Yasunari Ubukata, Shohei Yamaguchi, Hiroyuki Orita, Naoki Izawa, Saburo Kakizoe, Mototsugu Shimokawa, Tomoharu Yoshizumi, Yoshihiro Kakeji, Masaki Mori, Eiji Oki
Summary: This study evaluates the safety and efficacy of neoadjuvant chemotherapy with SOX130 in older patients with locally advanced gastric cancer. The results show that NAC-SOX130 is feasible for older patients, although careful monitoring of adverse events is necessary.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, Motohiro Kato, Hirotsugu Kenmotsu, Yasuhiro Kodera, Keigo Komine, Takafumi Koyama, Osamu Maeda, Mitsuru Miyachi, Hiroshi Nishihara, Hiroyuki Nishiyama, Shouichi Ohga, Wataru Okamoto, Eiji Oki, Shigeru Ono, Masashi Sanada, Ikuo Sekine, Tadao Takano, Kayoko Tao, Keita Terashima, Katsuya Tsuchihara, Yasushi Yatabe, Takayuki Yoshino, Eishi Baba
Summary: This article summarizes the efficacy of immune checkpoint inhibitors in the treatment of dMMR advanced solid tumors and proposes eight recommendations for proper MMR testing and selection of patients for immunotherapy.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Tomonori Nakanoko, Yasue Kimura, Keita Natsugoe, Kentaro Nonaka, Sho Nambara, Qingjiang Hu, Ryota Nakanishi, Mitsuhiko Ota, Eiji Oki, Tomoharu Yoshizumi
Summary: Due to the interference of the robotic arm, the dissection of the left recurrent nerve lymph nodes during robotic surgery is difficult. In this study, we developed a method of LRLN dissection with natural space creation and evaluated its short-term results.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Surgery
Tomonori Nakanoko, Eiji Oki, Mitsuhiko Ota, Naoki Ikenaga, Yuichi Hisamatsu, Takeo Toshima, Takahiro Kanno, Kotaro Tadano, Kenji Kawashima, Kenoki Ohuchida, Hajime Morohashi, Yuma Ebihara, Koshi Mimori, Masafumi Nakamura, Tomoharu Yoshizumi, Kenichi Hakamada, Satoshi Hirano, Norihiko Ikeda, Masaki Mori
Summary: In this study, the usefulness of telementoring using 3D drawing annotations in robotic surgery was examined. The results showed that the 3D annotation group had a shorter working time, fewer retries, and higher scores on the evaluation of robot skills compared to the control group.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Article
Surgery
Yuho Ebata, Yasue Kimura, Kentaro Nonaka, Sho Nambara, Qingjiang Hu, Ryota Nakanishi, Tomonori Nakanoko, Mitsuhiko Ota, Eiji Oki, Tomoharu Yoshizumi
Summary: Esophagectomy is a valuable option for treating esophageal strictures in patients with SSc. Therefore, surgical approaches should be established for SSc patients.
SURGICAL CASE REPORTS
(2023)
Meeting Abstract
Oncology
Kentaro Nonaka, Makoto Iimori, Eiji Oki, Yoshihiko Maehara, Tomoharu Yoshizumi, Hiroyuki Kitao
Meeting Abstract
Oncology
Eiji Oki
Meeting Abstract
Oncology
Qingjiang Hu, Takaaki Masuda, Eiji Oki, Koshi Mimori, Tomoharu Yoshizumi